Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.
1 report, 1 independent
Updated Jun 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The FDA and European Medicines Agency engaged in joint coordination regarding regulatory dossier evaluation.Sub-event
Omeros's drug received FDA approval and is now under EMA review.1 source
Keep exploring
The entities involved
-
Omeros Corporation
company in Seattle, United States
Nothing else this week.
- FDA
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.
- The European Medicines Agency provided a positive opinion on a drug developed by Novartis.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- EMA adopted a positive opinion and the European Commission granted marketing authorization for the drug Hopledo.
- Oncopeptides AB's drug received a positive opinion from the EMA, leading to the European Commission making a final decision for the EU market.